이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Mega Lifesciences 과거 수익 실적

과거 기준 확인 3/6

Mega Lifesciences은 연평균 14.3%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 증가했으며, 연간 11%였습니다. 매출은 연평균 8.9%의 비율로 증가했습니다. Mega Lifesciences의 자기자본이익률은 20.3%이고 순이익률은 12.8%입니다.

주요 정보

14.3%

수익 성장률

14.2%

EPS 성장률

Pharmaceuticals 산업 성장	12.4%
매출 성장률	8.9%
자기자본 수익률	20.3%
순이익	12.8%
다음 실적 업데이트	13 Aug 2024

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Mega Lifesciences 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

SET:MEGA 수익, 비용 및 수입 (THB Millions )
날짜	수익	수익	G+A 비용
31 Mar 24	15,718	2,017	4,230
31 Dec 23	15,716	1,993	4,191
30 Sep 23	15,442	1,919	4,278
30 Jun 23	15,693	2,042	4,352
31 Mar 23	15,634	2,081	4,398
31 Dec 22	15,727	2,242	4,359
30 Sep 22	15,116	2,338	4,068
30 Jun 22	15,061	2,292	4,054
31 Mar 22	14,724	2,227	3,924
31 Dec 21	14,172	1,947	3,769
30 Sep 21	14,395	1,878	3,767
30 Jun 21	13,775	1,607	3,538
31 Mar 21	12,809	1,406	3,331
31 Dec 20	12,613	1,393	3,288
30 Sep 20	12,168	1,348	3,169
30 Jun 20	11,642	1,288	3,137
31 Mar 20	11,655	1,205	3,195
31 Dec 19	11,164	1,139	3,176
30 Sep 19	10,950	1,163	3,198
30 Jun 19	10,712	1,136	3,153
31 Mar 19	10,569	1,203	3,113
31 Dec 18	10,284	1,206	3,052
30 Sep 18	10,147	1,183	3,041
30 Jun 18	9,937	1,175	3,010
31 Mar 18	9,829	1,178	2,988
31 Dec 17	9,624	1,113	2,965
30 Sep 17	9,514	1,023	2,928
30 Jun 17	9,282	945	2,869
31 Mar 17	8,968	873	2,766
31 Dec 16	8,828	795	2,674
30 Sep 16	8,514	771	2,603
30 Jun 16	8,226	756	2,658
31 Mar 16	8,115	703	2,714
31 Dec 15	7,966	696	2,718
30 Sep 15	7,775	675	2,668
30 Jun 15	7,862	634	2,580
31 Mar 15	7,851	598	2,486
31 Dec 14	7,749	548	2,471
30 Sep 14	7,620	474	2,454
30 Jun 14	7,422	516	2,362
31 Mar 14	7,226	567	2,304
31 Dec 13	7,055	624	2,236
30 Sep 13	6,812	593	2,190

양질의 수익: MEGA 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: MEGA 의 현재 순이익 이익률 (12.8%) 작년보다 낮습니다 (13.3%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: MEGA 의 수입은 지난 5년 동안 매년 14.3% 씩 증가했습니다.

성장 가속화: MEGA 은(는) 지난 1년 동안 마이너스 수익 성장을 기록했기 때문에 5년 평균과 비교할 수 없습니다.

수익 대 산업: MEGA 은 지난 1년 동안 마이너스 수익 성장( -3% )을 기록하여 Pharmaceuticals 업계 평균( 6.8% ).

Mega Lifesciences 과거 수익 실적

과거 기준 확인 3/6

주요 정보

최근 과거 실적 업데이트

First quarter 2024 earnings released: EPS: ฿0.55 (vs ฿0.52 in 1Q 2023)

Full year 2023 earnings released: EPS: ฿2.29 (vs ฿2.57 in FY 2022)

Mega Lifesciences Public Company Limited to Report Q3, 2024 Results on Nov 12, 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Mega Lifesciences Public Company Limited to Report Q2, 2023 Results on Aug 11, 2023

Recent updates

First quarter 2024 earnings released: EPS: ฿0.55 (vs ฿0.52 in 1Q 2023)

Upcoming dividend of ฿0.80 per share

Final dividend reduced to ฿0.80

Mega Lifesciences Public Company Limited Proposes Dividend for the Year Ended December 31, 2023, Payable on April 22, 2024

Full year 2023 earnings released: EPS: ฿2.29 (vs ฿2.57 in FY 2022)

Now 20% undervalued

Mega Lifesciences Public Company Limited to Report Q3, 2024 Results on Nov 12, 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Now 21% undervalued

Now 21% undervalued

Upcoming dividend of ฿0.80 per share at 3.8% yield

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2023to June 30, 2023, Payable on September 8, 2023

Now 20% undervalued after recent price drop

Mega Lifesciences Public Company Limited to Report Q2, 2023 Results on Aug 11, 2023

Now 25% undervalued after recent price drop

First quarter 2023 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of ฿0.85 per share at 3.5% yield

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Now 21% undervalued after recent price drop

Upcoming dividend of ฿0.75 per share

Second quarter 2022 earnings: Revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2022 to June 30, 2022, Payable on September 9, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Upcoming dividend of ฿0.86 per share

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited Proposes Dividend for Year Ended December 31, 2021, Payable on April 22, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ฿0.70 (vs ฿0.39 in 3Q 2020)

Investor sentiment improved over the past week

Upcoming dividend of ฿0.52 per share

Second quarter 2021 earnings released: EPS ฿0.58 (vs ฿0.35 in 2Q 2020)

First quarter 2021 earnings released: EPS ฿0.38 (vs ฿0.37 in 1Q 2020)

New 90-day low: ฿35.50

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS ฿1.60 (vs ฿1.31 in FY 2019)

New 90-day high: ฿40.50

New 90-day high: ฿39.00

Third quarter 2020 earnings released: EPS ฿0.39

Revenue and earnings beat expectations

New 90-day low: ฿32.00

New 90-day low: ฿33.00

Mega Lifesciences Public Company Limited (SET:MEGA) completed the acquisition of 83.33% stake in PT Futamed Pharmaceuticals from PT Ersons and others for approximately IDR 180 billion.

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기